Eli Lilly (LLY) Cash & Current Investments (2009 - 2026)

Eli Lilly has reported Cash & Current Investments for 18 years, with the latest figure at $5.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 64.0% year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 64.0% YoY), and the FY2025 full-year result was $7.3 billion, up 112.34% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $5.3 billion, down from $7.3 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $9.9 billion in Q3 2025, with the low at $2.2 billion in Q4 2022.
• Historically, Cash & Current Investments has averaged $3.8 billion across 5 years, with a median of $3.2 billion in 2025.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 43.41% — and 2025, when it jumped 181.76%.
• Eli Lilly's Cash & Current Investments stood at $2.2 billion in 2022, then soared by 32.37% to $2.9 billion in 2023, then advanced by 16.91% to $3.4 billion in 2024, then jumped by 112.34% to $7.3 billion in 2025, then retreated by 27.33% to $5.3 billion in 2026.
• The last three Cash & Current Investments figures came in at $5.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $9.9 billion (Q3 2025), per Business Quant data.